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Abstract
Background: Dengue is an important medical problem, with symptoms ranging from mild dengue fever to severe forms of
the disease, where vascular leakage leads to hypovolemic shock. Cytokines have been implicated to play a role in the
progression of severe dengue disease; however, their profile in dengue patients and the synergy that leads to continued
plasma leakage is not clearly understood. Herein, we investigated the cytokine kinetics and profiles of dengue patients at
different phases of illness to further understand the role of cytokines in dengue disease.
Methods and Findings: Circulating levels of 29 different types of cytokines were assessed by bead-based ELISA method in
dengue patients at the 3 different phases of illness. The association between significant changes in the levels of cytokines
and clinical parameters were analyzed. At the febrile phase, IP-10 was significant in dengue patients with and without
warning signs. However, MIP-1b was found to be significant in only patients with warning signs at this phase. IP-10 was also
significant in both with and without warning signs patients during defervescence. At this phase, MIP-1b and G-CSF were
significant in patients without warning signs, whereas MCP-1 was noted to be elevated significantly in patients with
warning signs. Significant correlations between the levels of VEGF, RANTES, IL-7, IL-12, PDGF and IL-5 with platelets; VEGF
with lymphocytes and neutrophils; G-CSF and IP-10 with atypical lymphocytes and various other cytokines with the liver
enzymes were observed in this study.
Conclusions: The cytokine profile patterns discovered between the different phases of illness indicate an essential role in
dengue pathogenesis and with further studies may serve as predictive markers for progression to dengue with warning
signs.
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Introduction
In certain infectious diseases, shock may occur due to excessive
plasma leakage and this leakage is often postulated to be caused by
endothelial sieves created by inappropriate cytokine responses in
the host. Dengue, traditionally classified as Dengue Fever (DF),
Dengue Haemorrhagic Fever (DHF) and Dengue Shock Syn-
drome (DSS) is one such disease where a key feature of DHF is
vascular leakage which then leads to hypovolemic shock (DSS),
inevitably increasing the chances of fatality. Recently, WHO has
suggested a new classification for this disease, which includes
dengue with or without warning signs and severe dengue [1].
Dengue, although with a low mortality rate, is one of the highest
morbidity rated arthropod diseases. It is endemic in more than 120
countries around the world, with 55% of the world’s population at
risk of being infected [1]. Despite being around for centuries, there
have not been any effective vaccines, therapeutics or anti-viral
drugs for this disease. The lack of such ‘‘cure’’ can be attributed to
firstly, to an incomplete understanding of dengue immunopatho-
genesis, secondly, a lack of a suitable animal model and finally the
inherent dangers of live vaccines [2].
Some of the postulated hypotheses on dengue immunopatho-
genesis include (i) the antibody enhancement theory [3,4], (ii)
cross-reactive memory T cells activation [5] and (iii) the original
antigenic sin [6], where all in a way cause either an over
production or a skewed profile of cytokine release, hence the term
cytokine storm/cytokine tsunami. This cytokine storm has a direct
effect on the vascular endothelial cells by increasing capillary
permeability and causing leakage [7]. Cytokines also exhibit
synergism, where for example, tumor necrosis factor-alpha (TNF-
a), interferon-c (IFN-c) and interleukin-1 (IL-1) together can
increase the capillary permeability compared to when the cytokine
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is acting alone [8]. There is also the inapparent ability of the
endothelium to repair itself which could be a result of some aspect
of endothelial dysfunction, though this has not been shown.
The study of permeability and leakage in dengue is often
applied with the use of human umbilical vein endothelial cell
(HUVEC) line where in one such study, Anderson et al. observed
that these cells are activated when exposed to culture fluids from
dengue virus (DENV)-infected peripheral blood mononuclear cells
(PBMCs) [9]. In another study, the vascular permeability of
HUVECs was found to be increased when exposed to either
recombinant human monocyte chemo-attractive protein-1
(rhMCP-1) or to the culture supernatant of DENV2-infected
human monocytes [10]. Moreover, certain cell lines, such as
DENV-infected primary human monocytes and epithelial cell lines
have shown increased production of cytokines [11]. DENV
infections of HepG2 and primary dendritic cells (DCs) have also
shown the ability to induce the production of cytokines such as IL-
8, RANTES, macrophage inhibitory protein-1-alpha (MIP-1a)
and MIP-1b [12].
The cytokine storm hypothesis has also been studied by
analyzing sera of DHF/DSS patients in Vietnam, India and
Cuba, which indeed showed the presence of elevated levels of IFN-
c, TNF-a and IL-10 [13,14,15]. A recent study on dengue infected
Venezuelan patients had documented significant increased levels
of MCP-2, IP-10 and TRAIL in patients’ serum during the febrile
period [16].
Despite extensive research on the role of cytokines in the
progression of severe dengue [17,18,19,20], the cytokine profiles,
especially at the defervescence stage, and the synergy between
them that leads to continued plasma leakage is not clearly
understood. Thus, in this study, not only did we attempt cytokine
profiling of dengue patients, but also set to establish patient and
cytokine kinetics throughout the phases of illness. We opted to gain
preliminary insights on differences in the levels of cytokines in
primary and secondary dengue infections. With that, we
endeavoured to analyse the relationship between the cytokines
and the clinical parameters of dengue patients.
Materials and Methods
Ethics Statement and Study Population
Five millilitres of blood were obtained from 44 DENV infected
patients at the University Malaya Medical Centre (UMMC),
Kuala Lumpur, Malaysia from January 2005 to June 2009 with
written informed consent. Blood was drawn at three time point of
illness- febrile, defervescence and convalescence for each patient.
The febrile phase usually lasts for 2–7 days and often has
indistinguishable clinical symptoms, whereas defervescence is the
critical stage where patient may develop severe signs and the
convalescence stage is when the patient starts to recover. The
2009 WHO dengue classification scheme and case definition [1]
was used to diagnose patients. Data on demographic character-
istics (i.e. age, gender and race), clinical features (i.e. day of fever,
body temperature, bleeding manifestation, leakage, abdominal
pain and hypotension) and routine haematological and biochem-
ical laboratory test findings (i.e. full blood count, liver function
tests) were also collected. Healthy donors’ blood samples that are
of age, gender and race matched with patients, were obtained
from Blood Bank, UMMC as controls. All data analysed were
anonymized and ethical clearance for this work was approved by
the Scientific and Ethical Committee of UMMC (Ethics Com-
mittee/IRB Reference No: 321.4).
Sera Isolation and Dengue Confirmatory Tests
Blood serum was collected by centrifugation of blood containing
tubes at 1500 rpm for 10 minutes and the serum was stored at
280uC until further use. All patients were further confirmed to
have dengue by detection of (i) DENV via virus isolation; (ii)
DENV RNA via real-time SYBR-Green based RT-PCR assay
[21]; (iii) DENV antigen via NS1 assay (Pan-E dengue early
ELISA kit; Panbio, Queensland, Australia); (iv) DENV-specific
antibodies via in-house capture IgM Enzyme-Linked Immunosor-
bent Assay (ELISA) [22] and haemagglutination inhibition (HI)
test [23]. The HI assay was also used to define primary and
secondary DENV infection based on the total antibody in paired
sera.
Identification and Quantification of Cytokines
Twenty-nine different cytokines, namely IL-1b, IL-1ra, IL-2,
IL-4, IL-5, Il-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-13, IL-15, IL-
17, IL-18, IP-10, ICAM-1, IFN-c, MCP-1, MIP-1a, MIP-1b,
Eotaxin, basic-fibroblast growth factor (FGF-Basic), granulocyte
colony-stimulating factor (G-CSF), granulocyte macrophage col-
ony-stimulating factor (GM-CSF), platelet-derived growth factor
(PDGF), vascular endothelial growth factor (VEGF), RANTES,
TNF-a were evaluated. The cytokine levels in the serum of all
patients and controls, at all 3 different phases of illness (febrile,
defervescence, and convalescence) were analyzed using the Bio-
Plex human cytokine 27-plex panel, 8-plex panel and 2-plex panel
kits (Bio-Plex Human Cytokine Assay; Bio-Rad Inc., Hercules,
CA, USA). Briefly, patients’ serum samples were mixed with beads
coated with antibodies (Abs) to various cytokines, having unique
Table 1. Demographics of study cohort.
Demographics Number/Range (Mean)
DwoWS DwWS SD
Number of patients 11 29 4
Gender F-6; M-5 F-11; M-18 F-3; M-1
Age (years) 14–57 (29) 14–67 (30) 15–60 (39)
Duration of illness (days) 2–15 (6) 2–14 (6) 4–13 (7)
Body temperature (6C) 36.0–40.3
(37.5)
35.8–40.2 (37.8) 35.8–39.7 (37.8)
DwoWS: Dengue without Warning Signs; DwWS: Dengue with Warning Signs;
SD: Severe Dengue; F: Female; M: Male.
doi:10.1371/journal.pone.0052215.t001
Table 2. Clinical symptoms experienced by study population.
Clinical Symptoms Number of Patients
DwoWS DwWS SD
Abdominal pain 0 16 2
Hypotension 2 6 2
Bleeding manifestation* 7 18 4
Plasma leakage 0 27 4
Co-morbidities# 0 3 1
DwoWS: Dengue without Warning Signs; DwWS: Dengue with Warning Signs;
SD: Severe Dengue;
*bleeding manifestation in DwoWS does not include mucosal bleeding;
#Co-morbidities observed include diabetes mellitus, hypertension,
hypercholesterolemia and asthma.
doi:10.1371/journal.pone.0052215.t002
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fluorescent intensity. Subsequently, the mixtures were incubated
with biotinylated anti-cytokine Abs. Finally, PE-conjugated
streptavidin was added, and the fluorescent signals were detected
using the multiplex array reader Bio-Plex 200 System (Bio-Rad
Laboratories). Raw data was initially measured as the relative
fluorescence intensity and then converted to cytokines concentra-
tion based on the standard curve generated from the reference
concentrations supplied in the kit (Bio-Rad Laboratories).
Statistical Analysis
The Kruskal-Wallis one way analysis of variance (ANOVA),
followed by Dunn’s multiple comparison test were used to evaluate
differences between raw cytokine levels in the different groups of
dengue patients compared to control groups. The Mann-Whitney
U Test was applied to assess differences in the cytokine levels of
primary and secondary infections. To establish the correlation
between cytokine levels and clinical parameters/findings, the
correlation matrix was applied. Results are given as correlation
coefficient, r (ranges from 21 to +1). Two-tailed P value of less
than 0.05 was considered to be significant for all test performed.
All three statistical analyses performed were done using GraphPad
Prism 5 for Windows, Version 5.01 (San Diego, California, USA).
Results
Characteristics of Study Population
Forty-four adult patients with laboratory confirmed dengue
virus infection were investigated for their cytokine profiles. These
patients were classified by the WHO 2009 guideline into 11 with
‘‘Dengue without Warning Signs (DwoWS)’’, 29 with ‘‘Dengue
with Warning Signs (DwWS) and 4 with ‘‘Severe Dengue (SD)’’.
The 24 males and 20 females study cohort consisted of 24 Malays,
4 Chinese, 13 Indians and 3 of other ethnicities. The
demographics and clinical parameters (age, duration of illness,
temperature, platelet count, and hematocrit) as well as clinical
symptoms (bleeding manifestation, plasma leakage, abdominal
pain and hypotension) are described in Table 1 and Table 2.
Table 3. Liver enzyme profile of study population.
Liver enzymes Difference vs normal levels (mean levels)
Normal DwoWS DwWS SD
Level (Range) Feb Def Conv Feb Def Conv Feb Def Conv
Total Bilirubin (mmol/L) 3–17 – – – – – – – q (25.2) q (50.5)
Total Albumin (g/L) 35–50 – – – – – – Q (32) Q (27.7) Q (29.5)
Aspartate Transaminase (AST) (IU/L) 15–37 q (117.4) q (179.2) q (71.8) q (121.6) q (144.5) q (125.6) q (115.5) q (778.8) q (530.5)
Alanine Transaminase (ALT) (IU/L) 30–65 q (115.0) q (155.5) q (107.5) q (101.2) q (135.4) q (149.8) q (80) q (207.7) q (268.5)
Alkaline phosphatase (ALP) (IU/L) 50 to 136 – – – – – – – q (204.5) q (201.5)
Gamma glutamyl transferase (Gamma-
GT) (IU/L)
15 to 85 – q (126.1) – – q (127.1) – – q (234.8) q (194)
DwoWS: Dengue without Warning Signs; DwWS: Dengue with Warning Signs; SD: Severe Dengue; Feb: Febrile; Def: Defervescence; Conv: Convalescence;Q: decrease in
mean levels; q: increase in mean levels; –indicates no mean differences compared to the normal levels.
doi:10.1371/journal.pone.0052215.t003
Table 4. Blood and white blood cells profile of study population.
Blood and White Blood Cells Difference vs normal levels (mean levels)
Normal DwoWS DwWS SD
Level(Range) Feb Def Conv Feb Def Conv Feb Def Conv
Platelet (106/mL) 150–400 – Q
(108.3)
– Q
(119.70)
Q (81.68) – Q (131.5) Q (57.17) –
HCT (%) 36–50 – – – – – – – – Q (32.5)
White Blood Cells (WBC)
(6109/L)
4–11 – – – Q
(3.66)
– – – – –
Neutrophils (%) 40–75 – – Q
(36.25)
– – – – – Q (38.00)
Lymphocytes (%) 20–45 – – q
(47)
– – – – – q (54.00)
Monocytes (%) 2 to 10 q
(10.17)
– q
(10.25)
– q (10.43) q (12.00) – – –
Atypical lymphocytes (%) 0 to 1 – q
(6.83)
– q (6.75) q (12.00) q (10.50) – q (6.25) –
DwoWS: Dengue without Warning Signs; DwWS: Dengue with Warning Signs; SD: Severe Dengue; Feb: Febrile; Def: Defervescence; Conv: Convalescence;Q: decrease in
mean levels; q: increase in mean levels; –indicates no mean differences compared to the normal level.
doi:10.1371/journal.pone.0052215.t004
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The liver function tests (Table 3) included measurement of total
bilirubin (TB), total albumin (TA), aspartate transaminase (AST),
alanine transaminase (ALT), alkaline phosphatase (ALP) and
gamma glutamyl transferase (GGT). Whereas, the white blood cell
(WBC) profile (Table 4) of this study population includes WBC,
neutrophils, lymphocytes, monocytes and atypical lymphocytes.
From the lab diagnostic tests performed (Table 5), DENV was
successfully isolated from 17 patients and DENV RNA was
detected in 31 patients. All the 4 DENV serotypes were detected
in our study cohort, with the highest percentage to be DENV-1
(43.3%) and the rest ranging from 13.3%–23.3%. DENV NS1
antigen was detected 27 patients. Serologically, 41 patients were
found to be IgM positive and amongst them, 37 had IgM
seroconversion during the defervescence or convalescence stage.
From the HI test, 16 patients had primary infections whereas the
rest were experiencing either presumptive or confirmed secondary
infections.
Levels of Cytokines at Different Phases of Illness
The levels of 29 different types of cytokines in dengue patients
were determined at the febrile, defervescence and convalescent
phases. In this analysis, the 4 severe dengue patients were excluded
due to the small sample size. We then categorized the cytokines
into 3 groups: (i) inflammatory cytokines; (ii) chemokines; (iii)
adhesion molecules and growth factors. The cytokines which
demonstrated significant differences between the different groups
of patients and controls are as summarized in Table 6.
i. Inflammatory cytokines (Figure 1A). Fifteen different
inflammatory cytokines were analyzed where the majority of them
were pro-inflammatory while only 4 were anti-inflammatory. Of
these, various trends were observed, notably, among the pro-
inflammatory cytokines, with only the mean cytokine levels of IL-
18 were elevated for both groups of patients at all three phases of
illness. The levels of pro-inflammatory cytokines, IL-5 and IL-12
as well as anti-inflammatory cytokine IL-4 were lower throughout
the illness in both groups when compared to the healthy controls.
The IFN-c levels were generally lower in DwoWS patients and
were higher in DwWS patients with decreasing trend as patients
recovered. The cytokines IL-1b and TNF-a displayed a similar
trend where lower levels were detected during febrile phase, which
then peaked during defervescence. The levels of IL-6 were
generally higher in DwWS patients, but during defervescence,
DwoWS patients had high levels similar to the warning signs
group. Both groups displayed higher levels of IL-9 than controls,
but the patients with warning signs had peak levels during
defervescence. Anti-inflammatory cytokines, IL-10 and IL-13
showed mixed patterns, whereas IL-1ra in both groups displayed
similar a trend throughout the disease, however with the warning
signs group having higher levels than the DwoWS patients. Two
cytokines (IL-2 and IL-17) had insufficient patient response in both
groups. Despite the various trends observed, none of the
inflammatory cytokines were significantly different between the
groups studied at any time point.
ii. Chemokines (Figure 1B). More than half of the
chemokines analysed, namely IP-10, MCP-1, MIP-1b, and
RANTES, had elevated mean cytokine levels in both patient with
and without warning signs across the three time points. Notably,
IP-10 levels in both groups were significantly different from
healthy donors at febrile (DwoWS: P,0.01; DwWS: P,0.001)
and defervescence (DwoWS: P,0.001; DwWS: P,0.01) phases
(Figure 2A). In the case of MIP-1b, a significant difference was
noted in the DwoWS during defervescence (P,0.01) and in the
DwWS patients in the febrile phase (P,0.05) of disease compared
to the controls (Figure 2B). Further, the MCP-1 was significantly
higher (P,0.01) in the warning signs patients during the febrile
stage when compared to the controls (Figure 2C). Eotaxin was
generally lower in DwoWS patients and higher in DwWS patients
and IL-8 was higher in patients without warning signs compared
to the DwWS.
iii. Adhesion molecules and growth factors
(Figure 1C). The only adhesion molecule studied, ICAM-1,
had mean levels that were slightly elevated in both groups of
patients. In contrast, the mean levels of growth factors, FGF-Basic
and G-CSF, were decreased in both groups relative to normal
groups at all the three phases of illness, with a significant decrease
for G-CSF in the patients’ without warning signs (P,0.05)
(Figure 2D) during defervescence. Other growth factors, IL-7,
PDGF and VEGF were generally lower in patients with warning
Table 5. Laboratory diagnostic assay results in the study
cohort.
Laboratory diagnostic assays DwoWS DwWS SD
Virus Isolation 2 12 3
DENV RNA detection 5 22 4
DENV NS1 Antigen detection 5 19 3
DENV IgM detection 10 28 3
Seroconversion 9 27 1
Haemagglutination Inhibition 11 29 4
Primary 4 11 1
Secondary 7 18 3
DwoWS: Dengue without Warning Signs; DwWS: Dengue with Warning Signs;
SD: Severe Dengue.
doi:10.1371/journal.pone.0052215.t005
Table 6. Significant cytokines at different phases of illness when compared to the controls.
Cytokines Controls (pg/ml) Acute (pg/ml) Defervescence (pg/ml) Convalescence
IP-10 1114.696250.45 DwoWS qq (43516.26612188.23) DwoWS qq (35574.1266509.15) –
DwWS qq (58880.3467867.14) DwWS qq (26983.0163042.01)
MCP-1 84.11612.80 DwWS qq (438.87691.41) – –
MIP-1b 102.49612.53 DwWS qq (662.816380.06) DwoWS qq (618.366163.05) –
G-CSF 65.31613.16 – DwoWS QQ (23.5662.05) –
DwoWS: Dengue without Warning Signs; DwWS: Dengue with Warning Signs; qq: significant increase compared to controls (p,0.05); QQ: significant decrease
compared to controls (p,0.05); – : no significant changes observed between group.
doi:10.1371/journal.pone.0052215.t006
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signs, relative to both patients without warning signs and the
normal group. Growth factor GM-CSF lacked data for in group
without warning signs.
Levels of Cytokines in Primary Versus Secondary
Infections
The differences in cytokines levels were also assessed between
the 16 primary infected patients and the 28 patients who were
experiencing secondary infections. Of the 29 cytokines analyzed,
most displayed relatively similar levels in both infection statuses.
However, at the febrile phase, we found that 3 cytokines differed
significantly where eotaxin, IP-10 and ICAM-1 were significantly
higher in patient with secondary infections (Figure 3). At the
defervescence phase, on the other hand, pro-inflammatory
cytokine IFN-c, chemokine RANTES and growth factors, PDGF
as well as G-CSF, were found to be significantly higher in
primarily infected patients than those suffering from secondary
infections (Figure 3).
Relationship between Cytokines and Clinical Parameters
The possible associations between the levels of cytokines with
clinical presentation of our study cohort are described in Table 7.
Generally, in patients without warning signs, we found that the
decreased levels of platelet were associated with the decreasing
levels of VEGF and RANTES during defervescence. At this phase,
the augmented liver enzymes were associated with several
cytokines where AST was associated with increased levels of IL-
1ra and IL-10; ALT with IP-10 and Gamma-GT with IL-4, IL-12
and IL-9. In the convalescence phase, the increased levels of AST
were conversely related to the decreasing levels of MCP-1.
Whereas, the increased levels of VEGF at this time point, was
associated with the decreased levels of neutrophils and higher state
of lymphocytes.
Significant associations between the decreased levels of IL-7, IL-
12 and PDGF with the decreased levels of platelet were observed
in patients with warning signs during the febrile phase, whereas in
the defervescence, another 3 cytokines (IL-5, RANTES and
VEGF) were also associated with platelet levels. In defervescing
DwWS patients, we also observed an association between the
Figure 1. Cytokine trends over the three different phases of illness. The mean levels of (A) inflammatory cytokines, (B) chemokines and (C)
adhesion molecules and growth factors in dengue patients without warning signs (DwoWS) (red symbol), dengue patients with warning signs
(DwWS) (blue symbol) and healthy controls (black line) at different phase of illness (Feb= Febrile; Def =Defervescence; Conv=Convalescence). Error
bars indicate standard error mean (SEM).
doi:10.1371/journal.pone.0052215.g001
Figure 2. Distribution of raw cytokine response values in dengue without warning signs (DwoWS) and dengue with warning signs
(DwWS) compared with healthy controls. Levels of (A) IP-10, (B) MIP-1b, (C) MCP-1 and (D) G-CSF in DwoWS (red symbol), DwWS (blue symbol)
patients at different phase of illness compared with control subjects (black symbol). The SEM are indicated by the error bars in the scatter plot.
Statistical significance based on the Kruskal-Wallis, Dunn’s multiple comparison test where *-P,0.05; **-P,0.01, and ***-P,0.001.
doi:10.1371/journal.pone.0052215.g002
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increased levels of atypical lymphocytes and the decreased levels of
G-CSF. While during convalescence, an association was noted
between the atypical lymphocytes and the decreasing levels of IP-
10 in these patients. The convalescing patients with warning signs
also showed association between the increased levels of IL-7 and
monocytes. At all 3 phases of illness, the increased levels of liver
enzyme AST was associated with various cytokines where in
febrile, ALT was correlated to increased levels of ICAM-1 and
decreased levels of FGF-Basic, IL-13, IL-4, IL-12 and VEGF.
During defervescence, AST was associated with decreased levels of
PDGF, whereas at convalescence, it was linked with the increased
levels of IL-10, and IFN-c.
Discussion
Generally, most hypotheses explaining dengue immunopatho-
genesis conclude that the overproduction and/or a skewed
cytokine response during the critical phase of disease causes
plasma leakage and hence, a more severe manifestation of dengue.
In this study, an analysis of various cytokines and their correlation
with dengue disease was performed.
Despite finding no significant difference in the levels of
inflammatory cytokines among patients with and without warning
signs as well as with the healthy controls, we showed trends of
various cytokines at the three different phases of illness.
Outstandingly, IL-15 which was higher in patients with warning
signs, has been known to be involved in T cell activation and
proliferation, and has been shown to be required for memory
CD8+ T cells division. In the absence of IL-2 (as noted in our
study, where many patients had undetectable levels of IL-2), the
levels of IL-15 is increased [24]. This could possibly enhance
proliferation of dengue memory T cells.
Interleukins-4, -5, -12 and -13 were clearly lower in dengue
patients than controls throughout the illness. IL-13, an effector
cytokine, synergizes with IL-2 to regulate IFN-c production [25],
and low levels of this cytokine could be attributed to the low level
of IFN-c in our cohort especially in patients without warning signs.
Regulatory cytokine IL-4, previously found to be increased in
DHF/DSS patients [26] has been indicated to play a role in
vascular permeability and with the exclusion of severe dengue
patients in our study, this may reflect the lower levels of IL-4
observed. This cytokine has also been known for immunoglobulin
class and subclass switch [27], and shift from Th1 to Th2 responses
in severe dengue, and this could possibly explain the lower levels in
patients without warning signs as they remain in a mild state of
infection.
Interferon-c has been shown to be increased in severe dengue
cases [28,29], and this is echoed in our study cohort with lower
number of severe dengue cases, where IFN-c was only slightly
higher in patients with warning signs. Another possibility of these
lower levels could be attributed to the low levels of IL-12, where an
in vivo study showed that IL-12 (p40 chain) - deficient mice had
decreased IFN-c production [30]. IL-12 and IL-18 together,
augment IFN-c production by activating Th1 cells [31], and in our
study, despite IL-18 being higher in dengue patients, still had
interferon levels that were negligible, implying that IFN-c
production by IL-12 is a co-induction with IL-18 and IL-18
induces IFN-c only when its receptor is upregulated by IL-12 [30].
Interleukin-10 showed a decreasing trend in patients without
warning signs, however remained high in DwWS patients
throughout the disease in concordance with several studies that
have suggested IL-10 in dengue pathogenesis [15,32]. An
important modulator in vascular leakage, platelet-activating factor
(PAF) and T cell apoptosis, the over-expression of IL-10 in
transgenic mice have demonstrated inhibition of TNF-a produc-
tion, where in our study TNF-a remained generally at a lower
level.
A study in Brazil, demonstrated a correlation between MIP-1b
and NK cells, suggesting its role in dengue protective mechanism
[33]. This was again shown in another study where MIP-1b was
higher in mild dengue than severe dengue [29], which is in line
with our findings where this chemokine was significantly higher in
patients without warning signs.
IP-10, an important mediator in inflammatory response, was
shown to inhibit dengue infection through competitive binding of
heparan sulphate on host cell membrane [34,35]. Initially during
the febrile and defervescence stage, both groups of patients
demonstrated significant high levels of IP-10, however, the levels
declined steadily for patients without warning signs throughout the
phases. However, it remained high in patients with warning signs,
offering a possibility that it may be affecting vascular permeability
as IP-10 is a potent inhibitor of angiogenesis in vivo [36].
An MCP-1 deficient mice model was unable to switch into
subclass Th2 responses [37] and this chemokine has been
Figure 3. Comparison of mean cytokine levels in primary and secondary dengue infections. Primary and secondary infection status was
determined by haemagglutination inhibition assay. Mean with SEM of seven cytokines (three at febrile phase of illness and 4 at defervescence).
Statistical significance based on the Mann-Whitney U test where *-P,0.05 and **-P,0.01.
doi:10.1371/journal.pone.0052215.g003
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associated with permeability changes in endothelial cells, where
alterations occur to the tight junctions of vascular endothelial cells
and leading to plasma leakage in dengue patients [38,39,40]. In
this study, significantly elevated levels of MCP-1 were found at the
febrile phases of patients with warning signs compared to healthy
individuals suggesting this chemokine as a possible biomarker in
dengue patients who are going to develop more severe clinical
outcome.
The infection status (primary versus secondary infections) of an
individual has also been disputed to be involved in the
pathogenesis of dengue, where most of the postulated theories
revolve around secondary infections. In our study, the main
limitation was the small sample size, hence we could not categorize
infection status by the respective dengue classification and hence
only decipher the cytokine levels of primary and secondary
infected dengue patients as a whole at different time point of
illness. Eotaxin, IP-10 and ICAM-1 were significantly higher in
secondary infected dengue patients during the febrile phase of
illness. Increased levels ICAM-1 have been indicated in endothe-
lium damage and activation [41,42], and 75% of the secondary
cases in our cohort were of patients with warning signs and/or
with severe dengue. Likewise, eotaxin levels which were higher in
patients with warning signs have been demonstrated to increase
permeability of human coronary artery endothelial cells by
downregulating tight junction proteins [43]. IP-10 levels were
significantly higher in the overall dengue patients, indicating a
more vigorous inflammatory response in secondary infections.
During the defervescence phase, 4 other cytokines displayed
significantly lower levels in secondary dengue cases, which were
IFN-c, RANTES, PDGF and G-CSF. Interferon-c is a critical
cytokine in the innate and adaptive immunity against viral
infections. Lower levels of this cytokine during a secondary
Table 7. Association of cytokines with clinical parameters in the study cohort.
Clinical Manifestations Coefficient (r) Clinical Manifestations Coefficient (r)
DwoWS (Defervescence) DwWS (Febrile)
Platelet: Platelet:
VEGF 0.862** IL-7 0.946***
RANTES 0.740* IL-12 0.607*
AST: PDGF 0.524*
IL-1ra 0.764* AST:
IL-10 0.756* ICAM-1 0.803*
ALT: FGF-Basic 20.898*
IP-10 0.574* IL-13 20.805**
Gamma-GT: IL-4 20.690*
IL-4 0.850** IL-12 20.636*
IL-12 0.752* VEGF 20.555*
IL-9 0.713* DwWS (Defervescence)
DwoWS (Convalescence) Platelet:
AST: IL-7 0.892***
MCP-1 20.980* PDGF 0.867***
Neutrophils: IL-5 0.662***
VEGF 20.960* RANTES 0.607*
Lymphocytes: VEGF 0.574**
VEGF 0.994** IL-12 0.547*
AST:
PDGF 20.416*
Atypical lymphocytes:
G-CSF 20.658*
DwWS (Convalescence)
AST:
IFN-c 0.964*
IL-10 0.950*
Monocytes:
IL-7 0.994**
Atypical lymphocytes:
IP-10 0.975*
DwoWS: Dengue without Warning Signs; DwWS: Dengue with Warning Signs; r: Correlation Coefficient; AST: aspartate transaminase; ALT: alanine transaminase; Gamma-
GT: Gamma glutamyl transferase. r = 1 indicates perfect correlation; r = 0 indicates X and Y do not vary together at all; r =21 indicates perfect negative correlation. P
values are based on two-tailed test and indicates the chances of random sampling, where *indicates P,0.05; **indicates P,0.01; ***indicates P,0.001.
doi:10.1371/journal.pone.0052215.t007
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infection indicate defective ability to inhibit viral replication or to
be immunomodulatory. RANTES recruits lymphocytes and NK
cells to sites of inflammation, and in an influenza mice model
deficient in RANTES/CCL5, delayed viral clearance and
excessive inflammation occurred [44]. PDGF which promotes
cellular proliferation and inhibits apoptosis and is an integral
component for maintaining the vascular networks [45] is lower in
secondary infections offering a possible explanation as to why
secondary infected patients suffered from vascular leakage. G-
CSF, a WBC stimulating factor, is lower in secondary infections in
line with the occurrence of leukopenia and neutropenia in such
cases [46,47].
In dengue patients without warning signs, a decrease in platelets
was noted during defervescence, and this was correlated strongly
with RANTES and VEGF. Both RANTES, a chemokine stored in
a-granules of platelets, secreted upon platelet activation [48], and
VEGF, a growth factor released by platelets, would be expected to
decrease upon thrombocytopenia. The defervescing DwoWS
patients also had increased levels of liver enzymes AST, ALT
and Gamma-GT. Raised AST levels during acute liver damage,
has been associated with secreted IL-1ra which is an acute phase
protein [49] produced by liver cells and also with IL-10, an anti-
inflammatory cytokine which have previously correlated to
necroinflammatory activity in liver damaged hepatitis C patients
[50]. ALT, an enzyme present in hepatocytes was linked to IP-10
which is known to be induced in the liver. This cytokine plays a
specific role in the intralobular accumulation of mononuclear cells
and/or the death of hepatocytes in chronic hepatitis [51]. The
gamma-GT levels, on the other hand were associated with IL-4,
IL-12 and IL-9. Schistosomal patients with hepatic damage were
found to have high levels of IL-4 [52] indicating an active Th2
immune response which could also be the situation in dengue
patients. Elevated levels of IL-12 have been shown to be associated
with liver damage in various studies conducted [53,54]. At the
convalescence phase, these without warning signs patients who
had high levels of monocytes were associated with the increased
levels of VEGF which possibly could be due to the involvement of
VEGF in monocytes activation [55]. Surprisingly though, VEGF
was inversely correlated to neutrophils. These patients also had
high AST levels which was negatively associated with the
decreasing levels of MCP-1 which have been implicated in the
liver injury process [56].
Dengue patients with warning signs also exhibited thrombocy-
topenia, however, this clinical feature began earlier during the
febrile phase and lasted till defervescence. A total of 6 different
cytokines were thought to have possible association with platelet
destruction, with 3 (IL-7, IL-12 and PDGF) occurring at both
febrile and defervescence. IL-12 has been known to stimulate
platelet-activating factor (PAF) [57] and the decrease of the
cytokine probably disallowed normal platelet aggregation and
degranulation. As mentioned earlier, the platelets are also known
to release several growth factors, which probably explain the
decreased levels of both VEGF and PDGF in the event of
thrombocytopenia. Elevated levels of IL-7, conversely, have been
previously shown to be involved in thrombocytosis [58]. During
defervescence, the low levels of IL-5 probably deregulated
functional PAF on eosinophils [59]. The presence of atypical
lymphocytes in patients with warning signs from defervescence
onwards was associated with G-CSF and IP-10.
The AST enzyme in dengue patients with warning signs was
raised throughout the illness, and this enzyme was associated (i) at
the febrile phase- ICAM-1, FGF-Basic, IL-13, IL-4, IL-12 and
VEGF; (ii) defervescence: PDGF and (iii) convalescence- IFN-c
and IP-10. ICAM-1 has been suggested to play a role in
inflammatory liver diseases [60] by recruiting leukocytes which
can injure tissue by releasing various proteases and oxidants. The
anti-inflammatory cytokines, IL-13 and IL-4 has been known to
have hepatoprotective effects [61,62]. IL-12 overexpression, as
pointed out earlier, had been involved in liver damage, and many
of its effects has been implied to be mediated by IFN-c [53]. IFN-c
has also been suggested to be a negative regulator in liver cell
proliferation and also to aggravate hepatitis viral-induced liver
damage [63]. In an adult liver, endothelial cells provide nutritional
and trophic support [64] and these cells are activated by VEGF
and PDGF, whereby an association of decreased levels of VEGF
was noticed with elevated levels of AST.
The main limitation in our study was the sample size number,
and even though all patients were accounted and tested for
cytokine levels at every phase of illness, some patients had
undetected response towards certain cytokines. Furthermore, we
did not include the severe dengue cases in our analyses as there
were only four of them, hence losing out on valuable information
as we could not establish cytokine trends/profile for severe dengue
patients. Despite all these, our findings managed to re-establish the
roles and dynamism of multiple cytokines at different phases of
illness according to the new WHO dengue classification. The
cytokine profiles from this study not only may have provided
probable prognostics markers for but also shed new insights in
dengue pathogenesis and this warrants further study. With the
recent advancement of cytokine adjuvants and anti-cytokine
therapies, our findings may serve towards better management in
the field of dengue which is currently lacking a vaccine.
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